Remdesivir Expanded Access

Note: This trial is no longer recruiting new patients.

Objective

Due to the lack of proven treatment options for COVID-19, the only medical intervention currently available to patients who develop severe or life-threatening illness is supportive care. Developing and researching potential treatments in an expedited fashion is a priority in combating this disease. Remdesivir is an investigational medication that has been approved by the FDA for compassionate use in patients with COVID-19 who have developed severe or life-threatening illness. Remdesivir is an antiviral medication that is designed to prevent proliferation of the virus within the body. It has been tested in hundreds of patients with SARS-CoV-2, the virus that causes COVID-19, and preliminary results suggest that the medication may improve clinical outcomes and prevent further disease progression.

Sponsor

• Gilead Sciences, Inc.

Principal Investigator

• Todd Freudenberger, MD

Contact

• Email the Clinical Research team

Location

Overlake Medical Center
1035 116th Ave NE 
Bellevue, WA 98004

Phone: (425) 688-5000

Resources

• ClinicalTrials.gov: Use NCT04323761 as the identifier to view a full description of this study.